← Back to Search

Vitamin

Riboflavin 0.1% ophthalmic solution for Keratoconus

N/A
Waitlist Available
Led By Stephen Trokel, MD
Research Sponsored by Stephen Trokel
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights

Study Summary

This trial is testing if brighter lights and shorter exposure times can be just as effective as current treatments for keratoconus and a bulging cornea.

Eligible Conditions
  • Keratoconus
  • Aneurysm

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Total Optical Aberrations of the Cornea following Cross-Linking

Trial Design

1Treatment groups
Experimental Treatment
Group I: 9 mw/cm2 at 10 minutes groupExperimental Treatment2 Interventions
30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes

Find a Location

Who is running the clinical trial?

Stephen TrokelLead Sponsor
2 Previous Clinical Trials
6 Total Patients Enrolled
1 Trials studying Keratoconus
Stephen Trokel, MDPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
6 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What ailments does Riboflavin 0.1% ophthalmic solution typically address?

"Riboflavin 0.1% ophthalmic solution is a common remedy for dietary and nutritional related issues, but can also be prescribed to address vitamin deficiencies, joint discomfort, and general supplementation needs."

Answered by AI

How many individuals are enrolling in this medical study?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, first made available on September 1st 2010, is actively recruiting participants. 30 patients are desired from one location in particular."

Answered by AI

Is enrollment still available in this clinical experiment?

"Indeed, the evidence on clinicaltrials.gov affirms that this trial is actively seeking volunteers. It was created in September of 2010 and edited as recently as August 2021; it aims to recruit 30 individuals from a solitary medical facility."

Answered by AI

Could you please explain other examinations involving Riboflavin 0.1% ocular solution?

"At present, 17 trials are assessing the efficacy of Riboflavin 0.1% ophthalmic solution, 8 of which have advanced to their third phase. San Francisco is where most studies take place but there are a total 44 medical sites running experiments with this medication."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What site did they apply to?
Edward Harkness Eye Institute-Columbia University Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Higher Irradiance in Keratoconus Ectasia
Stephen Trokel 2010. "Higher Irradiance in Keratoconus Ectasia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01789333.
~0 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top